Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.20), $0.10 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $24.63 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.